213 related articles for article (PubMed ID: 26325164)
1. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
Akaishi T; Shimazaki A; Tonouchi A; Ueda K; Miyawaki N; Kawazu K
J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
[TBL] [Abstract][Full Text] [Related]
2. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.
Kaarniranta K; Ikäheimo K; Mannermaa E; Ropo A
Clin Pharmacokinet; 2016 Apr; 55(4):485-94. PubMed ID: 26391697
[TBL] [Abstract][Full Text] [Related]
5. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
Holló G; Hommer A; Antón López A; Ropo A
J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
9. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
Konstas AG; Holló G
Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
[TBL] [Abstract][Full Text] [Related]
10. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy SM
Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
Lorenz K; Pfeiffer N
Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
[TBL] [Abstract][Full Text] [Related]
13. Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs.
Sakanaka K; Kawazu K; Tomonari M; Kitahara T; Nakashima M; Nishida K; Nakamura J; Sasaki H; Higuchi S
Biol Pharm Bull; 2008 Aug; 31(8):1590-5. PubMed ID: 18670094
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
Holló G; Katsanos A
Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol.
Fuwa M; Shimazaki A; Mieda M; Yamashita N; Akaishi T; Taniguchi T; Kato M
Sci Rep; 2019 May; 9(1):7491. PubMed ID: 31097790
[TBL] [Abstract][Full Text] [Related]
16. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
17. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
18. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma.
Holló G; Ropo A
Curr Med Res Opin; 2015 Jan; 31(1):13-6. PubMed ID: 25275411
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie M
J Glaucoma; 2012 Feb; 21(2):123-8. PubMed ID: 21423041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]